Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A Plus Biotechnology CoTPE:6918 -2.23%71 Return-on-Tangible-Asset is 10.16% as of Dec. 2025, which is 125% above its 10-year median of 4.51. GuruFocus rates TPE:6918 with a GF Score™ of 71/100 and a GF Value™ of NT$87.53 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 854 Medical Devices & Instruments companies, A Plus Biotechnology Co ranks better than 88.17% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. A Plus Biotechnology Co's annualizedNet Income for the quarter that ended in Dec. 2025 was NT$156.0 Mil. A Plus Biotechnology Co's average total tangible assets for the quarter that ended in Dec. 2025 was NT$1,535.1 Mil. Therefore, A Plus Biotechnology Co's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 10.16%.
The historical rank and industry rank for A Plus Biotechnology Co's Return-on-Tangible-Asset or its related term are showing as below:
TPE:6918'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -1.1 Med: 4.51 Max: 13.52
Current: 12.25
During the past 7 years, A Plus Biotechnology Co's highest Return-on-Tangible-Asset was 13.52%. The lowest was -1.10%. And the median was 4.51%.
TPE:6918's Return-on-Tangible-Asset is ranked better than 88.17% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.735
vs TPE:6918: 12.25
A Plus Biotechnology Co (TPE:6918) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
A Plus Biotechnology Co Return-on-Tangible-Asset Related Terms
A Plus Biotechnology Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for A Plus Biotechnology Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A Plus Biotechnology Co Return-on-Tangible-Asset Chart
TPE:6918 vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, A Plus Biotechnology Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
A Plus Biotechnology Co Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, A Plus Biotechnology Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where A Plus Biotechnology Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 10.16% mean?
A Plus Biotechnology Co (TPE:6918) has a Return-on-Tangible-Asset of 10.16% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on A Plus Biotechnology Co and its competitors. This is 125% above median its historical median of 4.51. According to the industry distribution chart, A Plus Biotechnology Co ranks #101 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 11.8%.
Is A Plus Biotechnology Co's Return-on-Tangible-Asset too high?
A Plus Biotechnology Co's current Return-on-Tangible-Asset of 10.16% is 125% above median its 10-year median of 4.51. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.74. A Plus Biotechnology Co's value of 10.16% is 1282.3% above this industry median. Based on the distribution chart, A Plus Biotechnology Co ranks #101 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, A Plus Biotechnology Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, A Plus Biotechnology Co ranks #101 out of 854 companies for Return-on-Tangible-Asset. This places A Plus Biotechnology Co in the top 12% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.74. A Plus Biotechnology Co's value of 10.16% is 1282.3% above this benchmark. While the company's 10-year median is 4.51 vs. the industry median of 0.74, A Plus Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.74, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. A Plus Biotechnology Co's current Return-on-Tangible-Asset of 10.16% is 1282.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on A Plus Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. A Plus Biotechnology Co's current Return-on-Tangible-Asset is 10.16%, which is 125% above median its own 10-year median of 4.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.53, compared to a current price of NT$70.10 — trading 19.9% below its estimated fair value. The current Return-on-Tangible-Asset is 10.16%, which is 125% above median its 10-year median of 4.51 and 1282.3% above the Medical Devices & Instruments industry median of 0.74. A Plus Biotechnology Co's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current Return-on-Tangible-Asset is 10.16% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?
Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued.
The current stock price of NT$70.10 is trading 19.9% below its estimated GF Value™ of NT$87.53.
GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.
Key valuation signals for TPE:6918:
Return-on-Tangible-Asset: 10.16% (125% above median its 10-year median of 4.51)
GF Value™: NT$87.53 vs. price of NT$70.10 (19.9% below fair value)
Industry Position: 1282.3% above the Medical Devices & Instruments median (#101 of 854)
No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
71GF Score
Get the complete analysis for TPE:6918
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6918 has been successfully added to your 
